Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants

ORAGENICS INC

Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.
Preferred Stock converts to common at $2.50 per share; warrants exercise at $25/share for 5 years.
Gross proceeds ~$16.5M; net ~$15M after fees; potential additional $16.5M if all warrants exercised.
Net proceeds to fund ONP-002 concussion trials, repay $3M bridge note, and general corporate purposes.
Preferred Stock carries 9% cumulative dividend payable in common stock; no voting rights except as law requires.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.4

ORAGENICS INC: Filing of Certificate of Designations for Preferred Stock.

Change: charter amendment

Exact text from the filing

The matters described in Item 1.01 of this Current Report on Form 8-K related to the filing of the Certificate of Designation is incorporated herein by reference.

View on SEC.gov

59 governance changes filed in the last 30 days. Browse all governance changes →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001641172-25-017575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.